查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950541

標靶治療黑色素瘤治療市場：按作用機制、給藥途徑、治療線、分銷管道和最終用戶分類－全球預測，2026-2032年

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，黑色素瘤標靶治療市場價值將達到 74.2 億美元，到 2026 年將成長至 80.6 億美元，複合年成長率為 9.32%，到 2032 年將達到 138.6 億美元。

關鍵市場統計數據
基準年 2025 74.2億美元
預計年份：2026年 80.6億美元
預測年份 2032 138.6億美元
複合年成長率 (%) 9.32%

簡明扼要而又全面地介紹了分子標靶治療和免疫調節如何重新定義黑色素瘤治療的臨床策略和商業性動態。

分子標靶治療將分子生物學與治療目標結合，重塑了黑色素瘤的臨床治療模式。過去十年，致癌性通路抑制劑和免疫查核點調節劑的進步，使治療方法從「一刀切」式轉變為精準治療，從而更好地應對腫瘤異質性和抗藥性機制。本入門指南整合了定義黑色素瘤分子標靶說明現狀的科學原理、不斷發展的臨床實踐和商業性趨勢。

客觀地檢驗分子診斷、聯合治療策略和支付方預期如何重塑黑色素瘤治療的臨床實踐和商業模式

在科學突破、監管先例和不斷發展的臨床實踐的推動下，黑色素瘤的治療模式發生了變革性變化。分子診斷和次世代定序的創新使得BRAF突變疾病和其他可治療的基因改變能夠被精準識別，從而使臨床醫生能夠更一致、更恰當地選擇適合BRAF和MEK抑制劑治療的患者。同時，標靶CTLA-4和PD-1通路免疫查核點抑制劑為多種患者群體帶來持久療效奠定了基礎，促使人們重新評估何時以及如何應用標靶藥物和免疫療法。

2025年美國關稅調整對黑色素瘤藥物供應鏈、採購慣例和臨床取得的影響策略分析

貿易政策趨勢和關稅調整有可能對全球藥品供應鏈、生產經濟和分銷策略產生不成比例的影響。到2025年，美國關稅政策的變化可能會透過多個相互關聯的途徑影響黑色素瘤治療生態系統，從上游原料藥採購到下游分銷成本以及醫院系統的採購行為。

從多維度細分觀點，將黑色素瘤治療中的臨床和商業性需求與作用機制、給藥途徑、治療方案、通路和臨床環境聯繫起來。

要了解市場，需要根據作用機制、給藥途徑、治療線、分銷管道和最終用戶進行細緻的細分，因為每個維度都會影響不同的臨床決策點、商業性槓桿和營運挑戰。依作用機制，治療方法可分為BRAF抑制劑、CTLA-4抑制劑、MEK抑制劑和PD-1抑制劑。 BRAF抑制劑包括Dabrafenib、Encorafenib和Vemurafenib等藥物；CTLA-4抑制劑包括Ipilimumab；MEK抑制劑包括比美替尼、Cobimetinib替尼和Trametinib；PD-1抑制劑包括Nivolumab和Pembrolizumab。每種分子類別對患者選擇、毒性管理和聯合治療策略都有不同的影響，它們的競爭動態也反映了專利狀態、適應症和臨床成熟度的差異。

區域情報簡報重點介紹美洲、歐洲、中東和非洲以及亞太地區獨特的監管、報銷和准入趨勢及其戰略影響。

區域趨勢在靶向黑色素瘤療法的可及性、監管策略和商業性優先順序的製定中發揮關鍵作用。在美洲，完善的法規結構和精準診斷的高普及率促進了已通過核准的標靶治療和免疫療法的快速應用，但支付方覆蓋範圍和各州採購政策的差異可能導致可及性不均衡。因此，在該地區運營的製造商必須解決診斷可及性方面的差異，同時調整其報銷申請和真實世界證據的生成，以滿足區域支付方的期望。

對領先的生物製藥公司如何利用轉化科學、診斷夥伴關係和供應鏈韌性來保持其在黑色素瘤治療領域的領先地位進行了深入評估。

黑色素瘤標靶治療領域的主要企業融合了深厚的臨床經驗、專注的研發投入和策略聯盟。業界領導者正利用強大的轉化平台推動新型BRAF和MEK抑制劑的研發，同時大力投資免疫腫瘤學項目，以補充標靶治療。許多公司採用聯合療法開發模式，將激酶抑制劑與查核點抑制劑合併使用，以克服抗藥性機制並提高療效的持久性。

一套切實可行的、優先排序的策略行動方案，旨在幫助藥物研發者、支付者和醫療服務提供者將臨床突破轉化為永續的患者療效和商業性可行性。

產業領導者應採取一系列有針對性的行動，使科學研究機會與商業性現實相契合。首先，將臨床開發與穩健的生物標記策略相結合至關重要，這有助於最大限度地識別有效應答者，並支持與支付方進行價值評估。申辦者應設計能夠捕捉腫瘤反應、持久性和生活品質（QOL）終點的試驗，這些終點對臨床醫生和支付者都至關重要。其次，基於明確機制的聯合治療可以擴大臨床效益，但這些方案必須整合毒性緩解計畫和實際應用路徑。

本執行摘要的調查方法是一種混合方法，結合了專家訪談、文獻檢驗和三角綜合分析，以透明的方式呈現可靠的研究結果。

本執行摘要的調查方法結合了質性檢驗、嚴謹的二手資料驗證和迭代三角測量分析。定性研究包括對臨床研究人員、腫瘤藥劑師、醫院藥房經理和高階主管進行深度訪談，以確定實際應用中的促進因素、營運限制和未滿足的需求。二手資料研究則利用同儕審查文獻、監管指導文件、臨床試驗註冊庫和公司備案文件，建構全面的證據基礎，並檢驗從質性訪談中得出的結論。

這份簡明扼要的概述將分子創新、診斷整合和運作準備聯繫起來，為加速黑色素瘤治療中患者獲益提供了一條切實可行的途徑。

總之，目前黑色素瘤標靶治療處於分子精準醫學和免疫調節的交叉領域，這給相關人員帶來了複雜而又切實的策略挑戰。 BRAF和MEK抑制劑以及CTLA-4和PD-1路徑調節技術的進步已經建立了多種治療平台，而對聯合療法的重新關注旨在擴大每種治療方法的益處，同時控制重疊的毒性。在商業性，診斷、證據產生和供應穩定性的整合將決定哪些項目能夠成功，哪些項目難以實現廣泛且公平的可近性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依作用機轉分類的標靶治療市場

  • BRAF抑制劑
    • Dabrafenib
    • Encorafenib
    • Vemurafenib
  • CTLA-4抑制劑
  • MEK抑制劑
    • 比美替尼
    • Cobimetinib
    • Trametinib
  • PD-1抑制劑
    • Nivolumab
    • Pembrolizumab

9. 按給藥途徑標靶治療市場

  • 靜脈注射
  • 口服

10. 按治療線標靶治療市場

  • 一線治療
  • 二級治療
  • 三線及以後

第11章標靶治療市場（按分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章標靶治療市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 腫瘤中心

13. 各地區標靶治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章標靶治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國標靶治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國標靶治療市場

第17章：中國黑色素瘤標靶治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-4F7A6D4FD8CC

The Targeted Therapy Drugs for Melanoma Market was valued at USD 7.42 billion in 2025 and is projected to grow to USD 8.06 billion in 2026, with a CAGR of 9.32%, reaching USD 13.86 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.42 billion
Estimated Year [2026] USD 8.06 billion
Forecast Year [2032] USD 13.86 billion
CAGR (%) 9.32%

A concise yet comprehensive primer that explains how molecular targeting and immune modulation have redefined clinical strategy and commercial dynamics in melanoma treatment

Targeted therapy has reshaped the clinical approach to melanoma by aligning molecular biology with therapeutic intent. Over the past decade, advances in oncogenic pathway inhibitors and immune checkpoint modulation have replaced one-size-fits-all paradigms with precision strategies that address tumor heterogeneity and resistance mechanisms. This introduction synthesizes the scientific principles, clinical practice shifts, and commercial dynamics that define the current landscape of targeted therapies for melanoma.

At the molecular level, actionable mutations such as BRAF V600 and alterations in downstream MAPK signaling have provided clear targets for small-molecule inhibitors. Concurrently, immune-oncology agents that release inhibitory brakes on T cells have transformed long-term disease control for many patients. The interplay between targeted agents and immunotherapies now defines treatment sequencing, combinatorial regimens, and toxicity management. Clinicians and payers increasingly demand evidence of durable benefit and manageable safety profiles, prompting more rigorous comparative evaluations and biomarker-driven patient selection. As a result, commercialization strategies have evolved to emphasize companion diagnostics, value-based contracting, and real-world evidence generation.

This introduction frames the subsequent sections by highlighting how mechanistic innovation, regulatory evolution, and shifting commercial imperatives converge to create both opportunity and complexity for stakeholders across the melanoma care continuum.

A clear-eyed examination of how molecular diagnostics, combination strategies, and payer expectations are reshaping clinical practice and commercialization approaches in melanoma care

The melanoma treatment landscape has undergone transformative shifts driven by scientific breakthroughs, regulatory precedent, and evolving clinical practice. Innovations in molecular diagnostics and next-generation sequencing have enabled precise identification of BRAF-mutant disease and other actionable alterations, allowing clinicians to match patients with targeted BRAF and MEK inhibitors more consistently than ever before. At the same time, immune checkpoint inhibitors that target CTLA-4 and PD-1 pathways have become foundational for durable responses in a broad swath of patients, prompting a reassessment of how and when to deploy targeted small molecules versus immunotherapies.

These clinical advances have been paralleled by strategic changes in drug development and commercialization. Companies increasingly pursue combination regimens that strategically pair kinase inhibitors with immune-modulating agents to extend response duration and overcome adaptive resistance. Regulatory agencies have signaled flexibility for accelerated pathways when clear benefit is demonstrated, while emphasizing post-approval evidence generation. Payers and health systems are responding by demanding more robust comparative effectiveness and safety data, which in turn is shaping evidence generation plans from Phase II onward. Together, these shifts compel manufacturers and providers to adopt integrated approaches that coordinate diagnostics, therapy sequencing, and longitudinal patient management to achieve both clinical and economic value.

A strategic analysis of how U.S. tariff adjustments in 2025 can ripple across supply chains, procurement practices, and clinical access for melanoma therapies

Trade policy developments and tariff adjustments can exert outsized effects on global pharmaceutical supply chains, manufacturing economics, and distribution strategies. In 2025, changes in U.S. tariff policy have the potential to influence the melanoma therapeutics ecosystem through multiple, interacting channels, from upstream active pharmaceutical ingredient sourcing to downstream distribution costs and procurement behavior by hospital systems.

Manufacturers that rely on cross-border sourcing of raw materials and finished dosage forms may encounter higher input costs and longer lead times, forcing recalibration of inventory strategies and contract manufacturing relationships. In response, some companies may accelerate reshoring and dual-sourcing initiatives to mitigate exposure, but such transitions typically require capital investment and regulatory coordination. For distributors and hospital pharmacies, even modest increases in transportation and customs-related expenses can translate into tighter formulary negotiations and renewed focus on procurement efficiency. This pressure can also magnify the importance of strategic contracting for high-cost oncology agents, including increased use of outcomes-based arrangements or capped-reimbursement models.

Clinicians and trial sponsors should anticipate operational ripple effects as well. Delays in importation of specialized compounds, diagnostic kits, and supportive care products could affect trial enrollment timelines and real-world access to combination regimens. Regulatory and commercial leaders must therefore integrate trade-policy scenarios into contingency planning, supplier diversification, and pricing strategies to preserve continuity of care and maintain competitive positioning in a shifting policy environment.

A multidimensional segmentation perspective that links mechanism, administration route, treatment line, distribution pathway, and care setting to clinical and commercial imperatives in melanoma therapy

Understanding the market requires careful segmentation by mechanism of action, route of administration, treatment line, distribution channel, and end user, because each axis drives different clinical decision points, commercial levers, and operational challenges. Mechanism of action divides therapies into BRAF inhibitors, CTLA-4 inhibitors, MEK inhibitors, and PD-1 inhibitors, with the BRAF inhibitors category further represented by agents such as dabrafenib, encorafenib, and vemurafenib, the CTLA-4 class exemplified by ipilimumab, the MEK class including binimetinib, cobimetinib, and trametinib, and the PD-1 class typified by nivolumab and pembrolizumab. Each of these molecular classes influences patient selection, toxicity management, and combination strategy differently, and their competitive dynamics reflect differential patent landscapes, label indications, and clinical maturity.

Route of administration also shapes care pathways, with intravenous therapies imposing clinic-based infusion resources and monitoring demands while oral agents shift adherence and dispensing responsibilities to outpatient settings. Treatment line segmentation into first line, second line, and third line and beyond determines reimbursement pathways, sequencing logic, and the comparative evidence required for formulary placement. Distribution channels such as hospital pharmacy, online pharmacy, and retail pharmacy each bring distinct procurement models, inventory turnover characteristics, and patient access considerations. End users span ambulatory surgical centers, hospitals, and oncology centers, and operational realities at each site-ranging from infusion capacity to integrated multidisciplinary care-drive adoption patterns and patient throughput. Synthesizing these segmentation lenses reveals where clinical need, logistical capability, and commercial strategy intersect to create pockets of unmet need and competitive advantage.

A regional intelligence briefing that identifies distinct regulatory, reimbursement, and access dynamics across the Americas, EMEA, and Asia-Pacific and their implications for strategy

Regional dynamics play a pivotal role in shaping access, regulatory strategy, and commercial prioritization for targeted melanoma therapies. In the Americas, established regulatory frameworks and high adoption of precision diagnostics support rapid uptake of approved targeted agents and immunotherapies, yet heterogeneity in payer coverage and state-level procurement policies can create access variability. Manufacturers operating in this region must therefore tailor reimbursement dossiers and real-world evidence generation to regional payer expectations while addressing disparities in diagnostic availability.

Across Europe, the Middle East, and Africa, regulatory pathways vary widely and national health technology assessment processes exert strong influence over adoption timelines and pricing negotiations. Stakeholders in these markets face a dual challenge: harmonizing clinical data to meet multiple assessment bodies while deploying pricing strategies that reflect differential ability-to-pay and procurement mechanisms. In the Asia-Pacific region, a combination of accelerating oncology infrastructure, growing investment in molecular diagnostics, and diverse reimbursement environments creates both high-growth opportunity and operational complexity. Market entrants in Asia-Pacific must navigate country-specific regulatory requirements, local clinical practice patterns, and partnerships that facilitate distribution and diagnostic integration. Taken together, regional differentiation underscores the need for tailored market access strategies, adaptive supply chain planning, and localized evidence generation to translate scientific advances into patient impact.

An informed appraisal of how leading biopharma companies combine translational science, diagnostics partnerships, and supply resilience to sustain leadership in melanoma therapeutics

Leading companies in the melanoma targeted therapy space demonstrate a blend of deep clinical expertise, focused R&D investment, and strategic collaborations. Industry leaders leverage strong translational platforms to advance novel BRAF and MEK inhibitor chemotypes, while also investing substantially in immune-oncology programs that complement targeted approaches. Many firms adopt combination development frameworks that intentionally pair kinase inhibitors with checkpoint inhibitors to address mechanisms of resistance and improve durability of response.

Commercial strategies among these companies emphasize alignment between diagnostic commercialization and therapeutic rollout, recognizing that companion diagnostics are essential for optimal patient selection. Partnerships with diagnostic providers, academic centers, and contract research organizations accelerate clinical enrollment and post-market evidence gathering. Manufacturing and supply-chain resilience have become differentiators, with companies targeting regional capacity expansion and contract manufacturing diversification to reduce disruption risk. Intellectual property strategies focus on lifecycle management through label expansions, next-generation compounds with improved safety or specificity, and formulation innovations that support outpatient administration. Collectively, these corporate behaviors illustrate how integrated scientific, regulatory, and commercial capabilities translate into sustained market relevance and clinical impact.

A pragmatic and prioritized set of strategic actions for drug developers, payers, and providers to translate clinical breakthroughs into durable patient outcomes and commercial viability

Industry leaders should adopt a set of targeted actions that reconcile scientific opportunity with commercial realities. First, aligning clinical development with robust biomarker strategies will be essential to maximize responder identification and to support payer conversations about value. Sponsors should design trials that capture not only tumor response but also durability and quality-of-life endpoints that matter to clinicians and payers. Second, pursuing strategic combinations with clear mechanistic rationale can extend clinical benefit, but such programs must integrate toxicity mitigation plans and real-world implementation pathways.

Third, companies should proactively shore up supply chain resilience by diversifying raw-material sources and expanding regional manufacturing capacity to insulate commercial continuity from policy or logistical shocks. Fourth, engaging early with payers and health technology assessors through transparent evidence-generation plans will reduce time-to-access and facilitate innovative contracting approaches. Finally, providers and health systems should invest in diagnostic infrastructure and care coordination to ensure that advances in targeted therapy translate into consistent, equitable clinical outcomes. Together, these actions will help stakeholders convert scientific breakthroughs into sustainable patient benefit and commercial success.

A transparent explanation of the mixed-methods research approach combining primary expert interviews, secondary literature validation, and triangulated synthesis for robust insights

The research methodology underpinning this executive summary integrates primary qualitative inquiry with rigorous secondary-source validation and iterative triangulation. Primary research consisted of in-depth interviews with clinical investigators, oncology pharmacists, hospital formulary managers, and business leaders to surface real-world adoption drivers, operational constraints, and unmet needs. Secondary research drew on peer-reviewed literature, regulatory guidance documents, trial registries, and corporate filings to construct a comprehensive evidence base and to validate assertions derived from primary interviews.

Data synthesis involved cross-referencing clinical trial outcomes with regulatory milestones and published safety profiles to identify durable signals and persistent knowledge gaps. Where appropriate, expert opinion was used to contextualize emerging trends and to interpret complex interactions between therapeutic mechanisms and clinical practice. Quality assurance steps included source triangulation, expert validation of key findings, and review cycles to ensure clarity and factual accuracy. Limitations of the methodology are acknowledged, including potential selection bias in interview sampling and the dynamic nature of regulatory and clinical environments that can introduce new data post-analysis. Nonetheless, the mixed-methods approach provides a robust foundation for strategic insight and operational planning.

A concise concluding synthesis that ties molecular innovation, diagnostic integration, and operational readiness to practical paths for accelerating patient benefit in melanoma care

In conclusion, targeted therapy for melanoma now sits at the intersection of molecular precision and immune modulation, creating complex but tractable strategic imperatives for stakeholders. Advances in BRAF and MEK inhibition alongside CTLA-4 and PD-1 pathway modulation have established multiple therapeutic pillars, and the emerging focus on combination regimens seeks to extend the benefits of each class while managing overlapping toxicities. Commercially, the integration of diagnostics, evidence generation, and supply resilience will differentiate successful programs from those that struggle to achieve broad, equitable uptake.

Looking forward, leaders who align clinical development with payer evidence needs, invest in diagnostic and distribution infrastructure, and adopt flexible manufacturing and contracting approaches will be best positioned to convert scientific promise into consistent patient impact. Operational readiness, transparent engagement with regulatory and health technology assessment bodies, and a commitment to rigorous post-approval evidence will be the levers that determine how rapidly innovation translates into standard-of-care practice. The path from molecule to meaningful, durable patient benefit is navigable, but it requires coordinated action across scientific, regulatory, and commercial domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Therapy Drugs for Melanoma Market, by Mechanism Of Action

  • 8.1. BRAF Inhibitors
    • 8.1.1. Dabrafenib
    • 8.1.2. Encorafenib
    • 8.1.3. Vemurafenib
  • 8.2. CTLA-4 Inhibitors
  • 8.3. MEK Inhibitors
    • 8.3.1. Binimetinib
    • 8.3.2. Cobimetinib
    • 8.3.3. Trametinib
  • 8.4. PD-1 Inhibitors
    • 8.4.1. Nivolumab
    • 8.4.2. Pembrolizumab

9. Targeted Therapy Drugs for Melanoma Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Targeted Therapy Drugs for Melanoma Market, by Treatment Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Targeted Therapy Drugs for Melanoma Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Targeted Therapy Drugs for Melanoma Market, by End User

  • 12.1. Ambulatory Surgical Center
  • 12.2. Hospital
  • 12.3. Oncology Center

13. Targeted Therapy Drugs for Melanoma Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Targeted Therapy Drugs for Melanoma Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Targeted Therapy Drugs for Melanoma Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Targeted Therapy Drugs for Melanoma Market

17. China Targeted Therapy Drugs for Melanoma Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Bristol Myers Squibb Company
  • 18.9. Eli Lilly and Company
  • 18.10. GlaxoSmithKline plc
  • 18.11. Johnson & Johnson Services, Inc.
  • 18.12. Merck & Co., Inc.
  • 18.13. Novartis AG
  • 18.14. Pfizer Inc.
  • 18.15. Regeneron Pharmaceuticals, Inc.
  • 18.16. Roche Holding AG
  • 18.17. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DABRAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ENCORAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY VEMURAFENIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BINIMETINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COBIMETINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TRAMETINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ONCOLOGY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY BRAF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY MEK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA TARGETED THERAPY DRUGS FOR MELANOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)